Beteiligungsmeldung

DocMorris AG

Gemeinsam gemeldeter Anteil

15.013%

Threshold

Crossed upwards

Timeline

Published

15.04.2026

Transaction

14.04.2026

Voting rights breakdown

Erworbene Stimmrechte15.013%
Veräusserte Stimmrechte0%
Unter dem Schwellenwert0%

Gemeldete wirtschaftlich Berechtigte · 3

Eine einzelne, gemeinsam eingereichte Meldung: Der Stimmrechtsanteil gilt für die gesamte Gruppe, nicht für jede Person.

Notice details

KategorieGroup of shareholders
BörseXSWX

Meldungs-ID

ZA02-000000000RYJ0

Beneficial owner

Jacek Szwajcowski

Gemeldete Adresse

Jacek Szwajcowski, Lodz, PL

On 26.02.2026, Pelion S.A. and Corporation of European Pharmaceutical Distributors N.V. have entered into an agreement that Pelion S.A. will sell to Corporation of European Pharmaceutical Distributors N.V. all shares in DocMorris AG it holds within 20 business days following the completion of the Annual General Meeting 2026 of DocMorris AG (i.e. by 12 June 2026 the latest, assuming the annual general meeting takes place on 12 May 2026). Such sale was notified by the group arrangement notified hereby by notice published on 05 March 2026. The settlement date of such sale of shares from Pelion S.A. to Corporation of European Pharmaceutical Distributors N.V. is not yet agreed, however, such settlement will only occur after the Annual General Meeting 2026 of DocMorris AG. Until settlement of such sale, Pelion S.A. will remain the shareholder of record of such DocMorris AG shares. As both Pelion S.A. and Corporation of European Pharmaceutical Distributors N.V. are beneficially owned by Jacek Szwajcowski and Zbigniew Molenda, such sale of shares from Pelion S.A. to Corporation of European Pharmaceutical Distributors N.V. does not result in a change of the beneficial ownership of such shares of DocMorris AG but a change of the persons directly involved in the group.

Diese Zahlen fassen öffentliche Meldungen zusammen. Sie stellen keine Anlageberatung dar.

Quelle: SIX Exchange Regulation

insider24.ch

Verpassen Sie kein Marktsignal mehr

Pro-AlarmeE-Mail und Telegram nach Veröffentlichung
Unbegrenzt Unternehmen verfolgenUnbegrenzte Watchlist mit dem Pro-Plan
MontagsrückblickDas Wichtigste zu Ihren Werten zur Eröffnung